Quantcast

Latest VaxGen Inc. Stories

2010-11-01 17:43:00

SOUTH SAN FRANCISCO, Calif., Nov. 1, 2010 /PRNewswire-FirstCall/ -- diaDexus, Inc. (OTC Bulletin Board: DDXS), a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today announced that the company, formerly known as VaxGen, Inc. and traded on the OTC Bulletin Board under the ticker symbol (VXGN), has been renamed diaDexus, Inc. diaDexus' common stock will continue to trade...

2010-07-28 21:35:00

SOUTH SAN FRANCISCO, Calif., July 28 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN) announced today the completion of its merger transaction with diaDexus, Inc., a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease. (Logo: http://photos.prnewswire.com/prnh/19991112/VAXGENLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO) As...

2010-05-28 08:00:00

SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical company, and diaDexus, Inc., a privately held diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, announced today that they have entered into a definitive agreement under which VaxGen will acquire diaDexus in a stock-for-stock merger. (Logo:...

2010-04-14 17:00:00

SOUTH SAN FRANCISCO, Calif., April 14 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical company, and diaDexus, Inc., a privately held diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, announced today that they have entered into a non-binding Summary of Terms pursuant to which it is contemplated that, if a definitive agreement is...

2010-02-04 05:00:00

SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN) announced preliminary results of the vote from its special stockholder meeting held on February 3, 2010. (Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO) VaxGen stockholders voted on two proposals. The first proposal, to approve and adopt the Agreement and Plan of Merger among OXiGENE, VaxGen, a wholly-owned subsidiary of OXiGENE, and James P. Panek as the VaxGen...

2010-01-25 12:09:00

SOUTH SAN FRANCISCO, Calif., Jan. 25 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN), announced today that Institutional Shareholder Services/Risk Metrics Group (ISS) and Glass, Lewis & Co. (Glass Lewis), two leading independent proxy advisory firms, recommend that VaxGen stockholders vote "FOR" the proposed merger of VaxGen, Inc. and OXiGENE, Inc. and "FOR" the Proposal to adjourn the VaxGen special meeting, if necessary, to solicit additional proxies if there are...

2009-09-25 08:00:00

SOUTH SAN FRANCISCO, Calif., Sept. 25 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN) today congratulated the Thai Ministry of Health, the U.S. Army, Sanofi Pasteur and VaxGen's licensee Global Solutions for Infectious Disease (GSID) on the encouraging results demonstrated in the RV144 clinical trial. The top-line results of the placebo controlled study in 16,000 Thai volunteers were released today, and according to the sponsors of the trial, demonstrated that the...

0c2661fb0da3126bddeda5ab42efe20d
2006-11-04 11:20:00

By PAUL ELIAS, AP Biotechnology Writer SAN FRANCISCO - VaxGen Inc.'s troubled $877.5 million federal contract to produce a new anthrax vaccine hit another snag Friday that delayed delivery of the shots a third time and jeopardized the struggling company's future. Food and Drug Administration is concerned the vaccine will lose its potency too fast to be effective and halted a pivotal human test of the experimental drug, the company said. In a conference call with analysts, VaxGen officials...

2006-03-17 07:26:10

WASHINGTON (Reuters) - California pharmaceutical firm VaxGen Inc. has further delayed shipment to the U.S. government a new version of its anthrax vaccine, an element of the U.S. bio-warfare defense program, The Washington Post reported on Friday. VaxGen Inc. officials said in interviews that their vaccine had failed in a key human trial, putting the company at least a year behind schedule, the newspaper said. The Brisbane, California-based company has an $877 million contract to...

2006-03-17 01:20:00

WASHINGTON (Reuters) - California pharmaceutical firm VaxGen Inc. has further delayed shipment to the U.S government a new version of its anthrax vaccine, an element of the U.S. bio-warfare defense program, the Washington Post reported on Friday. VaxGen Inc. officials said in interviews that their vaccine had failed in a key human trial, putting the company at least a year behind schedule, the newspaper said. The Brisbane, California-based company has an $877 million contract to supply 75...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related